Epigenomics-Guided Drug Development: Recent Advances in Solving the Cancer Treatment "jigsaw puzzle"

Area of Science:

• Biochemistry
• Genetics
• Pharmacology

Background:

• The human epigenome influences cellular identity and function.
• Genomics has been the primary focus in cancer drug discovery, but epigenomics is gaining attention.
• Approved epigenetic drugs target DNA and histone modifications, indicating therapeutic potential.

Purpose of the Study:

• To critically analyze epigenomics-guided drug discovery and development.
• To explore opportunities and challenges in the next decade of epigenomic drug development.
• To highlight the integration of epigenomic therapies with existing cancer treatments.

Main Methods:

• Review of current literature on epigenomics and drug discovery.
• Analysis of epigenetic editing techniques like CRISPR-Cas9 and ACE-seq.
• Evaluation of epigenetic drug screening methodologies.

Main Results:

• Epigenetic drugs targeting DNA and histone modifications are emerging, with some FDA/EMA-approved.
• Combining epigenetic editing tools with drug screens can identify novel small-molecule inhibitors.
• These inhibitors have the potential to reverse disease-associated epigenetic alterations.

Conclusions:

• Epigenomics-guided drug discovery presents significant opportunities for treating various diseases.
• Integrating epigenome-targeting drugs with chemotherapy and immunotherapy is crucial for innovative cancer treatment.
• Future advancements lie in leveraging epigenetic editing and screening technologies for therapeutic development.